236 related articles for article (PubMed ID: 27234841)
1. Evolution of hepatitis C virus in HIV coinfected patients under antiretroviral therapy.
Sede M; Parra M; Manrique JM; Laufer N; Jones LR; Quarleri J
Infect Genet Evol; 2016 Sep; 43():186-96. PubMed ID: 27234841
[TBL] [Abstract][Full Text] [Related]
2. Evaluating the impact of hepatitis C virus (HCV) on highly active antiretroviral therapy-mediated immune responses in HCV/HIV-coinfected women: role of HCV on expression of primed/memory T cells.
Al-Harthi L; Voris J; Du W; Wright D; Nowicki M; Frederick T; Landay A; Kovacs A
J Infect Dis; 2006 May; 193(9):1202-10. PubMed ID: 16586355
[TBL] [Abstract][Full Text] [Related]
3. Evolution of HVR-1 quasispecies after 1-year treatment in HIV/HCV-coinfected patients according to the pattern of response to highly active antiretroviral therapy.
Solmone M; Girardi E; Lalle E; Abbate I; D'Arminio Monforte A; Cozzi-Lepri A; Alessandrini A; Piscopo R; Ebo F; Cosco L; Antonucci G; Ippolito G; Capobianchi MR; ;
Antivir Ther; 2006; 11(1):87-94. PubMed ID: 16518964
[TBL] [Abstract][Full Text] [Related]
4. Hepatitis C virus (HCV) diversity in HIV-HCV-coinfected subjects initiating highly active antiretroviral therapy.
Blackard JT; Yang Y; Bordoni P; Sherman KE; Chung RT;
J Infect Dis; 2004 Apr; 189(8):1472-81. PubMed ID: 15073685
[TBL] [Abstract][Full Text] [Related]
5. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.
Antonucci G; Girardi E; Cozzi-Lepri A; Capobianchi MR; De Luca A; Puoti M; Petrelli E; Carnevale G; Rizzardini G; Grossi PA; Viganò P; Moioli MC; Carletti F; Solmone M; Ippolito G; Monforte AD; ;
Clin Infect Dis; 2005 Jun; 40(12):e101-9. PubMed ID: 15909251
[TBL] [Abstract][Full Text] [Related]
6. Longitudinal study in HIV/HCV-coinfected HAART-naive patients and role of HCV genotype.
Caudai C; Pianese M; Zacchini F; Toti M; Zazzi M; Valensin PE
J Clin Virol; 2005 Feb; 32(2):151-5. PubMed ID: 15653418
[TBL] [Abstract][Full Text] [Related]
7. HCV-specific T-cell responses in HIV/hepatitis C virus-coinfected patients on highly active antiretroviral therapy are comparable to those observed in hepatitis C virus-monoinfected individuals.
Rallón NI; Soriano V; Restrepo C; García-Samaniego J; Labarga P; López M; Peris A; González-Lahoz J; Benito JM
J Acquir Immune Defic Syndr; 2011 May; 57(1):1-8. PubMed ID: 21786458
[TBL] [Abstract][Full Text] [Related]
8. Cellular immune responses to HCV core increase and HCV RNA levels decrease during successful antiretroviral therapy.
Rohrbach J; Robinson N; Harcourt G; Hammond E; Gaudieri S; Gorgievski M; Telenti A; Keiser O; Günthard HF; Hirschel B; Hoffmann M; Bernasconi E; Battegay M; Furrer H; Klenerman P; Rauch A;
Gut; 2010 Sep; 59(9):1252-8. PubMed ID: 20660698
[TBL] [Abstract][Full Text] [Related]
9. Transient liver injury associated with the early recovery of HCV-specific T-cell responses and HCV rebound in HIV-1/HCV coinfected patients undergoing highly active antiretroviral therapy.
Kang F; Chen W; Zhang X; Nie W; Fu J; Xu X; Zhao P; Zhang X; Li W; Wang FS; Zhang Z; Zhao M
J Acquir Immune Defic Syndr; 2013 Feb; 62(2):135-42. PubMed ID: 23075912
[TBL] [Abstract][Full Text] [Related]
10. Impact of hepatitis C virus coinfection on T-cell dynamics in long-term HIV-suppressors under combined antiretroviral therapy.
Zaegel-Faucher O; Bregigeon S; Cano CE; Obry-Roguet V; Nicolino-Brunet C; Tamalet C; Dignat-George F; Poizot-Martin I
AIDS; 2015 Jul; 29(12):1505-10. PubMed ID: 26244390
[TBL] [Abstract][Full Text] [Related]
11. Fosamprenavir treatment in a highly active antiretroviral therapy schedule induces a HCV-RNA decrease and a Th1 network boost in HIV/HCV-coinfected patients.
Perrella A; Sbreglia C; D'Antonio A; Atripaldi L; Perrella O
Clin Microbiol Infect; 2010 Jun; 16(6):676-8. PubMed ID: 19681945
[TBL] [Abstract][Full Text] [Related]
12. Considerable under-treatment of chronic HCV infection in HIV patients despite acceptable sustained virological response rates in a real-life setting.
Reiberger T; Obermeier M; Payer BA; Baumgarten A; Weitner L; Moll A; Christensen S; Köppe S; Kundi M; Rieger A; Peck-Radosavljevic M
Antivir Ther; 2011; 16(6):815-24. PubMed ID: 21900713
[TBL] [Abstract][Full Text] [Related]
13. Stable recovery from HCV in HIV-HCV co-infection under antiretroviral therapy.
Zeitoun JD; Mallet V; Chaix ML; Viard JP; Blanche S; Pol S
J Clin Virol; 2007 Sep; 40(1):71-3. PubMed ID: 17658294
[TBL] [Abstract][Full Text] [Related]
14. Liver injury and changes in hepatitis C Virus (HCV) RNA load associated with protease inhibitor-based antiretroviral therapy for treatment-naive HCV-HIV-coinfected patients: lopinavir-ritonavir versus nelfinavir.
Sherman KE; Shire NJ; Cernohous P; Rouster SD; Omachi JH; Brun S; Da Silva B
Clin Infect Dis; 2005 Oct; 41(8):1186-95. PubMed ID: 16163639
[TBL] [Abstract][Full Text] [Related]
15. HCV Specific IL-21 Producing T Cells but Not IL-17A Producing T Cells Are Associated with HCV Viral Control in HIV/HCV Coinfection.
MacParland SA; Fadel SM; Mihajlovic V; Fawaz A; Kim C; Rahman AK; Liu J; Kaul R; Kovacs C; Grebely J; Dore GJ; Wong DK; Ostrowski MA
PLoS One; 2016; 11(4):e0154433. PubMed ID: 27124305
[TBL] [Abstract][Full Text] [Related]
16. Impact of HIV infection in patients infected with chronic HCV (genotypes 1a and 3a): virological and clinical changes.
Behzadpour D; Ahmadi Vasmehjani A; Mousavi Nasab SD; Ahmadi NA; Baharlou R
Pathog Glob Health; 2016; 110(7-8):310-315. PubMed ID: 27830997
[TBL] [Abstract][Full Text] [Related]
17. High serum HCV RNA in chronic hepatitis C patients coinfected with HIV despite successful antiretroviral therapy.
Barreiro P; Labarga P; de Mendoza C; Benítez-Gutiérrez L; Fernandez-Montero JV; Peña JM; Soriano V
Antivir Ther; 2016; 21(6):489-494. PubMed ID: 26887981
[TBL] [Abstract][Full Text] [Related]
18. Long-term suppression of plasma viremia with highly active antiretroviral therapy despite virus evolution and very limited selection of drug-resistant genotypes.
Pariente N; Pernas M; de la Rosa R; Gómez-Mariano G; Fernández G; Rubio A; López M; Benito JM; López-Galíndez C; Leal M; Domingo E; Martinez MA; Mas A
J Med Virol; 2004 Jul; 73(3):350-61. PubMed ID: 15170628
[TBL] [Abstract][Full Text] [Related]
19. Higher Activation in CD4(+) T Cells But Similar Viral Control Among HIV/Hepatitis C Virus-Coinfected Patients on a Simplification Monotherapy.
BenMarzouk-Hidalgo OJ; Torres-Cornejo A; Gutierrez-Valencia A; Ruiz-Valderas R; Viciana P; López-Cortés LF
AIDS Res Hum Retroviruses; 2016 Jan; 32(1):6-11. PubMed ID: 26414169
[TBL] [Abstract][Full Text] [Related]
20. Determinants of immunological and virological responses to antiretroviral therapy amongst HIV-infected adults in central Argentina: negative influence of hepatitis C infection.
Farías AA; Kremer LE; Allende L; Díaz Mdel P; Pisano MB; Contigiani MS; Ré VE
Trans R Soc Trop Med Hyg; 2013 Jul; 107(7):432-7. PubMed ID: 23761392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
